Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.2, 2012, Pages 89-93

  Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcoholic liver disease; Interleukin 10; Interleukin 22; Interleukin 6

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTICLE; BACTERIAL GROWTH; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; ENZYME INHIBITION; FATTY LIVER; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; LIVER TRANSPLANTATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UPREGULATION;

EID: 84856948223     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07003.x     Document Type: Article

References (44)

1. Yoon Y, Yi H. Liver Cirrhosis Mortality in the United States, 1970-2007 Surveillance report #88. NIAAA Homepage 2010. Cited August 2010. Available from URL:.
2. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J. Clin. Gastroenterol. 2011; 45: 714-19.
3. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-85.
4. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
5. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J. 2001; 15: 1335-49.
6. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002; 122: 2049-63.
7. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp. Biol. Med. (Maywood) 2003; 228: 882-90.
8. Gao B, Seki E, Brenner DA etal. Innate immunity in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 300: G516-25.
9. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-44.
10. Szabo G, Mandrekar P, Petrasek J etal. The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol. Clin. Exp. Res. 2011; 35: 782-6.
11. Mandal P, Park PH, McMullen MR etal. The anti-inflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-9.
12. Petrasek J, Dolganiuc A, Csak T etal. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011; 53: 649-60.
13. Wang H, Lafdil F, Kong X etal. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int. J. Biol. Sci. 2011; 7: 536-50.
14. Miller AM, Wang H, Park O etal. Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. Alcohol. Clin. Exp. Res. 2010; 34: 719-25.
15. Sun Z, Klein AS, Radaeva S etal. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003; 125: 202-15.
16. Wolk K, Witte E, Witte K etal. Biology of interleukin-22. Semin. Immunopathol. 2010; 32: 17-31.
17. Radaeva S, Sun R, Pan HN etal. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39: 1332-42.
18. Park O, Wang H, Weng H etal. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54: 252-61.
19. Zenewicz LA, Yancopoulos GD, Valenzuela DM etal. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-59.
20. Ren X, Hu B, Colletti LM. IL-22 is involved in liver regeneration after hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 298: G74-80.
21. Hill DB, Marsano L, Cohen D etal. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J. Lab. Clin. Med. 1992; 119: 547-52.
22. Horiguchi N, Wang L, Mukhopadhyay P etal. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008; 134: 1148-58.
23. Hong F, Kim WH, Tian Z etal. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene 2002; 21: 32-43.
24. Zhang X, Tachibana S, Wang H etal. Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology 2010; 52: 2137-47.
25. El-Assal O, Hong F, Kim WH etal. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell. Mol. Immunol. 2004; 1: 205-11.
26. Hong F, Radaeva S, Pan HN etal. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004; 40: 933-41.
27. Yan AW, Fouts DE, Brandl J etal. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105.
28. Cohen JI, Roychowdhury S, McMullen MR etal. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 2010; 139: 664-74.
29. Roychowdhury S, McMullen MR, Pritchard MT etal. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology 2009; 49: 1326-34.
30. Miller A, Wanf H, Bertola A etal. Inflammation-associated IL-6/STAT3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in IL-10 deficient mice. Hepatology 2011; 51: 846-56.
31. Yin S, Wang H, Park O etal. Enhanced liver regeneration in IL-10-deficient mice after partial hepatectomy via stimulating inflammatory response and activating hepatocyte STAT3. Am. J. Pathol. 2011; 178: 1614-21.
32. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 2000; 164: 1814-19.
33. Yang L, Zhang Y, Wang L etal. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J. Hepatol. 2010; 53: 339-47.
34. Xing WW, Zou MJ, Liu S etal. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci. Biotechnol. Biochem. 2011; 75: 1290-4.
35. Ki SH, Park O, Zheng M etal. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010; 52: 1291-300.
36. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N. Engl. J. Med. 2009; 360: 2758-69.
37. Boetticher NC, Peine CJ, Kwo P etal. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-60.
38. Louvet A, Wartel F, Castel H etal. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137: 541-8.
39. Naveau S, Chollet-Martin S, Dharancy S etal. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-7.
40. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007; 4: 24-34.
41. Aujla SJ, Kolls JK. IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 2009; 87: 451-4.
42. Zhang Y, Cobleigh M, Lian J etal. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011; 141: 1897-906.
43. Liang SC, Nickerson-Nutter C, Pittman DD etal. IL-22 induces an acute-phase response. J. Immunol. 2010; 185: 5531-8.
44. Jiang R, Tan Z, Deng L etal. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-9.